Literature DB >> 35733005

Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy.

Ana S Coroadinha1,2.   

Abstract

Lentiviral vectors are among the most used vectors in gene therapy to treat pathologies of different origins, such as cancers, rare monogenic diseases or neurological disorders. This chapter provides an overview on lentiviral vector developments in terms of vector design and manufacture for gene therapy applications. The state of the art of vector production will be summarized face to the recent developments contributing to improve vector safety, efficacy and manufacturing robustness, focusing on human immunodeficiency virus 1 (HIV-1) based lentiviral vectors. Transient and stable production systems will be discussed highlighting recent advances in producer cell line development. Challenges in lentiviral vector development upstream and downstream will be addressed with a particular focus on the improvements undertaken to increase vector yields and production scalability.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioreaction; Gene therapy; Lentivirus; Manufacture; Packaging cells; Production; Purification; Quality; Safety

Mesh:

Year:  2022        PMID: 35733005     DOI: 10.1007/978-1-0716-2441-8_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  52 in total

1.  Control of tumour vascular permeability.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-10-05       Impact factor: 15.470

2.  Retroviral vectors for human gene delivery.

Authors:  Sally McTaggart; Mohamed Al-Rubeai
Journal:  Biotechnol Adv       Date:  2002-04       Impact factor: 14.227

Review 3.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

4.  A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Authors:  Fengtao You; Yinyan Wang; Licui Jiang; Xuejun Zhu; Dan Chen; Lei Yuan; Gangli An; Huimin Meng; Lin Yang
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

Review 5.  Current progress in the gene therapy of cancer.

Authors:  B M Davis; O N Koc; K Lee; S L Gerson
Journal:  Curr Opin Oncol       Date:  1996-11       Impact factor: 3.645

Review 6.  Gene therapeutics and gene therapy for cancer.

Authors:  T Fujiwara; E A Grimm; J A Roth
Journal:  Curr Opin Oncol       Date:  1994-01       Impact factor: 3.645

7.  Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Authors:  Xiaobin Lu; Qiao Yu; Gwendolyn K Binder; Ziping Chen; Tatiana Slepushkina; John Rossi; Boro Dropulic
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility.

Authors:  Hillel Haim; Ignacio Salas; Joseph Sodroski
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 10.  Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.

Authors:  Nawid Albinger; Jessica Hartmann; Evelyn Ullrich
Journal:  Gene Ther       Date:  2021-03-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.